In 2017, the FDA approved the first anti-CD19 CART cell product, tisagenlecleucel, for relapsed and/or refractory B-cell precursor acute lymphoblastic leukemia (B-ALL) in pediatric and young adult patients. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.